Regeneron Pharmaceuticals Inc logo

REGN - Regeneron Pharmaceuticals Inc Share Price

$542.27 8.4  1.6%

Last Trade - 20/01/21

Large Cap
Market Cap £41.80bn
Enterprise Value £41.56bn
Revenue £6.05bn
Position in Universe 200th / 6566
Unlock REGN Revenue
Relative Strength (%)
1m +4.93%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -19.7%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
2,820 4,104 4,860 5,872 6,711 7,863 8,530 10,506 +22.8%
-18.4 +80.1 +37.4 +70.8 +57.4 -10.8 +64.4 +24.5
Balance Sheet
FINANCIAL BRIEF: : For the nine months ended 30 September 2020,Regeneron Pharmaceuticals Inc revenues increased 29% to$6.07B. Net income increased 79% to $2.36B. Revenuesreflect EYLEA segment increase from $1.19B to $3.6B, Sanofisegment increase from $175M to $869.3M. Net incomebenefited from Changes in the fair value of our equityincrease from $58.4M (expense) to $133.8M (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for REGN
Graphical History


REGN Revenue Unlock REGN Revenue

Net Income

REGN Net Income Unlock REGN Revenue

Normalised EPS

REGN Normalised EPS Unlock REGN Revenue

PE Ratio Range

REGN PE Ratio Range Unlock REGN Revenue

Dividend Yield Range

REGN Dividend Yield Range Unlock REGN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
REGN EPS Forecasts Unlock REGN Revenue
Profile Summary

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.

Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated January 11, 1988
Public Since January 1, 1991
No. of Shareholders: n/a
No. of Employees: 8,100
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite , Nasdaq 100 , S&P Composite 1500 , S&P 500 , S&P 500 Health Care (sector),
Exchange NASDAQ Global Select Market
Shares in Issue 106,706,264
Free Float (0.0%)
Eligible for
REGN Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for REGN
Upcoming Events for REGN
Thursday 4th February, 2021 Estimate
Q4 2020 Regeneron Pharmaceuticals Inc Earnings Release
Monday 3rd May, 2021 Estimate
Q1 2021 Regeneron Pharmaceuticals Inc Earnings Release
Frequently Asked Questions for Regeneron Pharmaceuticals Inc
What is the Regeneron Pharmaceuticals Inc share price?

As of 20/01/21, shares in Regeneron Pharmaceuticals Inc are trading at $542.27, giving the company a market capitalisation of £41.80bn. This share price information is delayed by 15 minutes.

How has the Regeneron Pharmaceuticals Inc share price performed this year?

Shares in Regeneron Pharmaceuticals Inc are currently trading at $542.27 and the price has moved by 38.33% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Regeneron Pharmaceuticals Inc price has moved by 21.91% over the past year.

What are the analyst and broker recommendations for Regeneron Pharmaceuticals Inc?

Of the analysts with advisory recommendations for Regeneron Pharmaceuticals Inc, there are there are currently 9 "buy" , 9 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Regeneron Pharmaceuticals Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Regeneron Pharmaceuticals Inc next release its financial results?

Regeneron Pharmaceuticals Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Regeneron Pharmaceuticals Inc dividend yield?

Regeneron Pharmaceuticals Inc does not currently pay a dividend.

Does Regeneron Pharmaceuticals Inc pay a dividend?

Regeneron Pharmaceuticals Inc does not currently pay a dividend.

When does Regeneron Pharmaceuticals Inc next pay dividends?

Regeneron Pharmaceuticals Inc does not currently pay a dividend.

How do I buy Regeneron Pharmaceuticals Inc shares?

To buy shares in Regeneron Pharmaceuticals Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Regeneron Pharmaceuticals Inc?

Shares in Regeneron Pharmaceuticals Inc are currently trading at $542.27, giving the company a market capitalisation of £41.80bn.

Where are Regeneron Pharmaceuticals Inc shares listed? Where are Regeneron Pharmaceuticals Inc shares listed?

Here are the trading details for Regeneron Pharmaceuticals Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: REGN
What kind of share is Regeneron Pharmaceuticals Inc?

Based on an overall assessment of its quality, value and momentum, Regeneron Pharmaceuticals Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Regeneron Pharmaceuticals Inc share price forecast 2021?

Shares in Regeneron Pharmaceuticals Inc are currently priced at $542.27. At that level they are trading at 23.73% discount to the analyst consensus target price of 0.00.

Analysts covering Regeneron Pharmaceuticals Inc currently have a consensus Earnings Per Share (EPS) forecast of 30.36 for the next financial year.

How can I tell whether the Regeneron Pharmaceuticals Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Regeneron Pharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been -27.72%. At the current price of $542.27, shares in Regeneron Pharmaceuticals Inc are trading at -6.02% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Regeneron Pharmaceuticals Inc PE Ratio?

The Regeneron Pharmaceuticals Inc PE ratio based on its reported earnings over the past 12 months is 19.51. The shares are currently trading at $542.27.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Regeneron Pharmaceuticals Inc?

Regeneron Pharmaceuticals Inc's management team is headed by:

Leonard Schleifer - PRE
George Yancopoulos - CPR
Neil Stahl - EVP
P. Roy Vagelos - CHM
Joseph Goldstein - IND
Michael Brown - IND
Daniel Van Plew - EVP
Christine Poon - IND
Joseph LaRosa - EVP
Robert Landry - CFO
Bonnie Bassler - IND
Christopher Fenimore - VPR
N. Anthony Coles - IND
Marion McCourt - SVP
Andrew Murphy - EVP
Who are the major shareholders of Regeneron Pharmaceuticals Inc?

Here are the top five shareholders of Regeneron Pharmaceuticals Inc based on the size of their shareholding:

Fidelity Management & Research Company LLC Investment Advisor
Percentage owned: 11.77% (12.3m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 7.62% (7.99m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 6.58% (6.90m shares)
Capital World Investors Investment Advisor
Percentage owned: 6.34% (6.64m shares)
State Street Global Advisors (US) Investment Advisor/Hedge Fund
Percentage owned: 4.44% (4.66m shares)
Similar to REGN
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.